Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
237 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Retinopathy - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape. Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 5, 1, 33, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.Diabetic Retinopathy. Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Diabetic Retinopathy Overview 10 Therapeutics Development 11 Pipeline Products for Diabetic Retinopathy - Overview 11 Pipeline Products for Diabetic Retinopathy - Comparative Analysis 12 Diabetic Retinopathy - Therapeutics under Development by Companies 13 Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes 17 Diabetic Retinopathy - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Diabetic Retinopathy - Products under Development by Companies 22 Diabetic Retinopathy - Products under Investigation by Universities/Institutes 26 Diabetic Retinopathy - Companies Involved in Therapeutics Development 27 Acucela Inc. 27 Aerie Pharmaceuticals, Inc. 28 Aerpio Therapeutics, Inc. 29 Amakem NV 30 Antisense Therapeutics Limited 31 Araim Pharmaceuticals, Inc. 32 BCN Peptides, S.A. 33 Biomar Microbial Technologies 34 Charlesson LLC. 35 Coherus BioSciences, Inc. 36 Crinetics Pharmaceuticals, Inc. 37 Diffusion Pharmaceuticals Inc 38 Dimerix Bioscience Pty Ltd 39 Dynamis Therapeutics, Inc. 40 EyeGene Inc 41 Foresee Pharmaceuticals, LLC 42 Formycon AG 43 Icon Bioscience, Inc. 44 Islet Sciences, Inc. 45 Kodiak Sciences Inc. 46 Kowa Company, Ltd. 47 LegoChem Biosciences, Inc 48 Lpath, Inc. 49 M's Science Corporation 50 Mabion SA 51 MingSight Pharmaceuticals 52 OcuCure Therapeutics, Inc. 53 Oculis ehf 54 Ohr Pharmaceutical Inc. 55 PanOptica, Inc. 56 Profarma 57 Promedior, Inc. 58 Regeneron Pharmaceuticals Inc 59 Retrotope, Inc 60 Ribomic Inc. 61 Stelic Institute & Co., Inc. 62 Stemedica Cell Technologies, Inc. 63 Strongbridge Biopharma plc 64 Sucampo Pharmaceuticals, Inc. 65 Targazyme, Inc. 66 ThromboGenics NV 67 TWi Pharmaceuticals, Inc. 68 VESSL Therapeutics Ltd 69 Diabetic Retinopathy - Therapeutics Assessment 70 Assessment by Monotherapy Products 70 Assessment by Combination Products 71 Assessment by Target 72 Assessment by Mechanism of Action 76 Assessment by Route of Administration 80 Assessment by Molecule Type 82 Drug Profiles 84 (irbesartan + propagermanium) - Drug Profile 84 A-717 - Drug Profile 87 AC-301 - Drug Profile 88 aflibercept - Drug Profile 89 AKB-9778 - Drug Profile 100 ALG-1001 - Drug Profile 104 AMA-0428 - Drug Profile 107 APTA-1004 - Drug Profile 108 Aptamers for Diabetic Retinopathy - Drug Profile 109 AR-13154 - Drug Profile 110 atesidorsen sodium - Drug Profile 111 Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 119 BNN-27 - Drug Profile 120 cibinetide - Drug Profile 121 CLT-005 - Drug Profile 124 CLT-020 - Drug Profile 125 COR-005 - Drug Profile 126 cyclosporine - Drug Profile 129 Cyndacel-M - Drug Profile 130 DMX-400 - Drug Profile 131 Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile 132 DT-23552 - Drug Profile 133 DYN-12 - Drug Profile 134 E-1086 - Drug Profile 135 EG-Mirotin - Drug Profile 136 emixustat hydrochloride - Drug Profile 137 FP-008 - Drug Profile 141 GLY-230 - Drug Profile 142 IB-09A0133 - Drug Profile 143 IVMED-60 - Drug Profile 144 JP-153 - Drug Profile 145 KSI-301 - Drug Profile 146 L-779976 - Drug Profile 147 LCB-030110 - Drug Profile 148 Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile 149 Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile 150 MS-553 - Drug Profile 151 MultiGeneEye - Drug Profile 152 Nextomabs - Drug Profile 153 NM-108 - Drug Profile 154 OC-10X - Drug Profile 155 OC-410 - Drug Profile 156 ocriplasmin - Drug Profile 157 OCU-200 - Drug Profile 163 OCX-063 - Drug Profile 164 OLX-302 - Drug Profile 165 PAN-90806 - Drug Profile 166 PF-07 - Drug Profile 168 PRM-167 - Drug Profile 169 Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 170 ranibizumab biosimilar - Drug Profile 171 ranibizumab biosimilar - Drug Profile 172 ranibizumab biosimilar - Drug Profile 174 RBM-008 - Drug Profile 175 Recombinant Protein for Oncology and Diabetic Retinopathy - Drug Profile 176 Recombinant Protein To Target Caspases for Diabetic Retinopathy, Macular Degeneration and Solid Tumor - Drug Profile 177 RES-529 - Drug Profile 178 ripasudil - Drug Profile 182 RT-001 - Drug Profile 184 RT-002 - Drug Profile 186 RTU-1096 - Drug Profile 187 somatostatin - Drug Profile 188 squalamine lactate - Drug Profile 189 Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 197 Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 203 STNM-1510 - Drug Profile 204 Synthetic Peptide to Agonize PEDF-R for Diabetic Retinopathy - Drug Profile 205 THR-687 - Drug Profile 206 TZ-101 - Drug Profile 207 V-1932 - Drug Profile 210 Wnt-001 - Drug Profile 211 Diabetic Retinopathy - Dormant Projects 212 Diabetic Retinopathy - Discontinued Products 218 Diabetic Retinopathy - Product Development Milestones 219 Featured News & Press Releases 219 Appendix 231 Methodology 231 Coverage 231 Secondary Research 231 Primary Research 231 Expert Panel Validation 231 Contact Us 231 Disclaimer 232
List of Tables
Number of Products under Development for Diabetic Retinopathy, H2 2016 16 Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2016 17 Number of Products under Development by Companies, H2 2016 18 Number of Products under Development by Companies, H2 2016 (Contd..1) 19 Number of Products under Development by Companies, H2 2016 (Contd..2) 20 Number of Products under Development by Companies, H2 2016 (Contd..3) 21 Number of Products under Investigation by Universities/Institutes, H2 2016 22 Comparative Analysis by Late Stage Development, H2 2016 23 Comparative Analysis by Clinical Stage Development, H2 2016 24 Comparative Analysis by Early Stage Development, H2 2016 25 Comparative Analysis by Unknown Stage Development, H2 2016 26 Products under Development by Companies, H2 2016 27 Products under Development by Companies, H2 2016 (Contd..1) 28 Products under Development by Companies, H2 2016 (Contd..2) 29 Products under Development by Companies, H2 2016 (Contd..3) 30 Products under Investigation by Universities/Institutes, H2 2016 31 Diabetic Retinopathy - Pipeline by Acucela Inc., H2 2016 32 Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 33 Diabetic Retinopathy - Pipeline by Aerpio Therapeutics, Inc., H2 2016 34 Diabetic Retinopathy - Pipeline by Amakem NV, H2 2016 35 Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited, H2 2016 36 Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 37 Diabetic Retinopathy - Pipeline by BCN Peptides, S.A., H2 2016 38 Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H2 2016 39 Diabetic Retinopathy - Pipeline by Charlesson LLC., H2 2016 40 Diabetic Retinopathy - Pipeline by Coherus BioSciences, Inc., H2 2016 41 Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 42 Diabetic Retinopathy - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 43 Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 44 Diabetic Retinopathy - Pipeline by Dynamis Therapeutics, Inc., H2 2016 45 Diabetic Retinopathy - Pipeline by EyeGene Inc, H2 2016 46 Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016 47 Diabetic Retinopathy - Pipeline by Formycon AG, H2 2016 48 Diabetic Retinopathy - Pipeline by Icon Bioscience, Inc., H2 2016 49 Diabetic Retinopathy - Pipeline by Islet Sciences, Inc., H2 2016 50 Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc., H2 2016 51 Diabetic Retinopathy - Pipeline by Kowa Company, Ltd., H2 2016 52 Diabetic Retinopathy - Pipeline by LegoChem Biosciences, Inc, H2 2016 53 Diabetic Retinopathy - Pipeline by Lpath, Inc., H2 2016 54 Diabetic Retinopathy - Pipeline by M's Science Corporation, H2 2016 55 Diabetic Retinopathy - Pipeline by Mabion SA, H2 2016 56 Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals, H2 2016 57 Diabetic Retinopathy - Pipeline by OcuCure Therapeutics, Inc., H2 2016 58 Diabetic Retinopathy - Pipeline by Oculis ehf, H2 2016 59 Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc., H2 2016 60 Diabetic Retinopathy - Pipeline by PanOptica, Inc., H2 2016 61 Diabetic Retinopathy - Pipeline by Profarma, H2 2016 62 Diabetic Retinopathy - Pipeline by Promedior, Inc., H2 2016 63 Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 64 Diabetic Retinopathy - Pipeline by Retrotope, Inc, H2 2016 65 Diabetic Retinopathy - Pipeline by Ribomic Inc., H2 2016 66 Diabetic Retinopathy - Pipeline by Stelic Institute & Co., Inc., H2 2016 67 Diabetic Retinopathy - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 68 Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc , H2 2016 69 Diabetic Retinopathy - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 70 Diabetic Retinopathy - Pipeline by Targazyme, Inc., H2 2016 71 Diabetic Retinopathy - Pipeline by ThromboGenics NV, H2 2016 72 Diabetic Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H2 2016 73 Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H2 2016 74 Assessment by Monotherapy Products, H2 2016 75 Assessment by Combination Products, H2 2016 76 Number of Products by Stage and Target, H2 2016 78 Number of Products by Stage and Mechanism of Action, H2 2016 82 Number of Products by Stage and Route of Administration, H2 2016 86 Number of Products by Stage and Molecule Type, H2 2016 88 Diabetic Retinopathy - Dormant Projects, H2 2016 217 Diabetic Retinopathy - Dormant Projects (Contd..1), H2 2016 218 Diabetic Retinopathy - Dormant Projects (Contd..2), H2 2016 219 Diabetic Retinopathy - Dormant Projects (Contd..3), H2 2016 220 Diabetic Retinopathy - Dormant Projects (Contd..4), H2 2016 221 Diabetic Retinopathy - Dormant Projects (Contd..5), H2 2016 222 Diabetic Retinopathy - Discontinued Products, H2 2016 223
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
